Litcius/Paper detail

Critical Assessment of Pharmacokinetic Drug–Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment

Vijayabhaskar Veeravalli, Ranjeet Prasad Dash, Jennifer A. Thomas, R. Jayachandra Babu, Lakshmi Mohan Vamsi Madgula, Nuggehally R. Srinivas

2020Drug Safety61 citationsDOI

Topics & Concepts

TofacitinibMedicineJanus kinase inhibitorRheumatoid arthritisPharmacologyPharmacokineticsDrugJanus kinaseDrug interactionTherapeutic drug monitoringInternal medicineCytokineRheumatoid Arthritis Research and TherapiesPeripheral Neuropathies and Disorders
Critical Assessment of Pharmacokinetic Drug–Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment | Litcius